Currently, out of the existing stock ratings of David Lebowitz - 90 which are a Buy (50.85%), 58 which are a Hold (32.77%), 29 which are a Sell (16.38%)

David Lebowitz

Work Performance Price Targets & Ratings Chart

Analyst David Lebowitz works at CITI and is covering the Healthcare sector with 404 price targets and ratings displayed on 21 stocks. Previously, David Lebowitz worked at MORGAN STANLEY.

David Lebowitz's average stock forecast success ratio is 60.45% with an average time for price targets to be met of 143.48 days.

Most recent stock forecast was given on IONS, Ionis Pharmaceuticals at 31-Jul-2023.

Wall Street Analyst David Lebowitz

Analyst best performing recommendations are on SNDX (SYNDAX PHARMACEUTICALS).
The best stock recommendation documented was for SNDX (SYNDAX PHARMACEUTICALS) at 3/11/2020. The price target of $10 was fulfilled within 1 day with a profit of $1.79 (15.18%) receiving and performance score of 151.82.

Average potential price target upside

of $64.05 (54.07%) on GWPH.
of $38.83 (29.84%) on ALNY (ALNYLAM PHARMACEUTICALS).
of $35.05 (28.43%) on ASND (ASCENDIS PHARMA A/S).

AKBA Akebia Therapeutics ALNY Alnylam Pharmaceuticals ARQT Arcutis Biotherapeutics ASND Ascendis Pharma A/S BPMC Blueprint Medicines GWPH IONS Ionis Pharmaceuticals IRWD Ironwood Pharmaceuticals KPTI Karyopharm Therapeutics MGNX MacroGenics RYTM Rhythm Pharmaceuticals SDGR Schrodinger SNDX Syndax Pharmaceuticals ZEAL Zealand Pharma A/S AVRO AVROBIO IMRX EPZM Epizyme MIRM Mirum Pharmaceuticals NTLA Intellia Therapeutics PLRX NBRV

Show more stocks

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average time for PT to be met

Performance score

Ed Arce (HCWAINWRIGHT)